Should anyone still care (and I'm not sure I do anymore), in today's installment of Death By A Thousand Cuts, they filed another 8K with the SEC to register yet another dilution/funding event to keep operations rolling (not that anyone has the first clue what those operations might be, since they stopped communicating with the world and the CEO has been invisible, per custom established by his predecessor). This placement is for $2,000,000, which should keep them going for a while (and maybe get the wheels turning on a clinical trial, finally?). Per another custom, we have no idea who the sugar daddy is, though I would imagine it is an insider. But who knows. VTRO is a black box, and nobody is allowed to know anything apparently. On that subject, I contacted the CFO a couple weeks ago. He was kind enough to respond, but it was unreadable gobbledygook jargon that said nothing. But, hey, at least he responded, even if it did sound suspiciously like it was crafted by an attorney.
Anyway, in separate news, the 8K also mentions that they have retained a business consultant on what amounts to a stock deal. Reading between the lines (since their "lines" rarely say anything anymore), it looks like this person's job is to push the floundering IPO over the top. Which would be great if s/he succeeds. Good luck with that, whoever you are. One does wonder what the point of an IPO is, if they can find investors willing to shell out $2,000,000. The IPO itself was downsized to $10,000,000.
Since we are left to conjecture, my take is they are doing what they have to do to survive, and perhaps get one of the trials started. Which is good, but it's also becoming clear that original investors are slowly being diluted into irrelevance. If someone from the Company would like to challenge that assertion, I am open to arguments.
